We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Federal investigators are looking into manufacturing issues at a Pfizer Inc. (PFE) plant that led to shortages of the EpiPen emergency treatment for allergic reactions.
Pfizer received a civil investigative demand from the U.S. Attorney's Office for the Southern District of New York seeking records and information related the issues, the New York drug maker said in a filing with the Securities and Exchange Commission.
The U.S. Food and Drug Administration in 2017 issued a warning letter to Pfizer's Meridian Medical Technologies unit over violations at the Brentwood, Mo., plant that makes the EpiPen auto-injector products for Mylan N.V. (MYL), which was forced to recall thousands of the devices.
Pfizer said it intends to produce records in response to the civil investigative demand.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 01, 2019 08:25 ET (13:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
